DGAP-News: aap receives funding for its innovative antibacterial silver coating technology

aap Implantate AG ("aap") announces that its innovative antibacterial silver coating technology receives funding from the German Federal Ministry of Education and Research ("BMBF"). aap shall first receive grants for costs arising within the scope of the preparation of the human clinical study for the aimed market approval of the silver coating technology of up to around EUR 0.7 million. The funding relates in particular to expenses in connection with the conception and qualification of the study. In a next step aap also aims to receive a funding to carry out the human clinical study, for which, however, a further application will be required.
 

The BMBF funding underlines the innovative character of aap's silver coating technology and its potential to significantly disburden healthcare systems at the cost level. The internationally IP-protected silver coating technology developed by aap is intended to protect the surface of implants from colonisation by bacteria. Thereby aap is addressing one of the biggest not adequately solved challenges in trauma: the reduction of surgical site infection (SSI) risks.
 

The benefit granted to the company (aap's contract number is KV-Aglm) is part of the "Healthcare Industry in the Medical Research Framework Programme" action area of the BMBF (= grant authority). It is granted, according to the BMBF, for projects on "Transferring Medical Technology Solutions to Patient Care - Verifying Clinical Evidence without Delay". As part of the funding programme small and medium-sized businesses (SMBs) are to be introduced to changing legal and regulatory framework conditions and assisted with the clinical validation of medical technology solutions. The swift transfer of innovations to healthcare is thereby to be promoted and the late failure risk of investments in research and development to be reduced. For further information please see the guidelines on the BMBF website at: https://www.bmbf.de/foerderungen/ bekanntmachung-1376.html.

 

------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany; Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de